NASDAQ:RGEN Repligen (RGEN) Stock Price, News & Analysis $148.92 -4.03 (-2.63%) (As of 11:08 AM ET) Add Compare Share Share Today's Range$148.54▼$153.4850-Day Range$119.79▼$167.3552-Week Range$110.45▼$211.13Volume47,532 shsAverage Volume652,669 shsMarket Capitalization$8.34 billionP/E Ratio595.70Dividend YieldN/APrice Target$189.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Repligen alerts: Email Address Repligen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside27.0% Upside$189.57 Price TargetShort InterestBearish8.43% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment0.90Based on 8 Articles This WeekInsider TradingSelling Shares$739,717 Sold Last QuarterProj. Earnings Growth34.48%From $1.45 to $1.95 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.83 out of 5 starsMedical Sector92nd out of 924 stocksBiological Products, Except Diagnostic Industry8th out of 145 stocks 4.4 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRepligen has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Repligen's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.43% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Repligen has recently increased by 3.78%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 68.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.33. Previous Next 3.3 News and Social Media Coverage News SentimentRepligen has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Repligen this week, compared to 5 articles on an average week.Search Interest5 people have searched for RGEN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold 64.40% more of their company's stock than they have bought. Specifically, they have bought $449,938.00 in company stock and sold $739,717.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Repligen's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to grow by 34.48% in the coming year, from $1.45 to $1.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 597.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.04.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 597.22, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 139.34.Price to Earnings Growth RatioRepligen has a PEG Ratio of 5.27. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 4.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Repligen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchFamous Stock Market Bull Issues Rare “Collapse” WarningTilson says we're in the midst of a collapse – unlike any we've seen since 2008. As you'll see, it all centers around the tech sector. And the epicenter – it turns out – is Apple.To watch his fascinating interview which has taken Wall Street by storm, click here. About Repligen Stock (NASDAQ:RGEN)Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More RGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGEN Stock News HeadlinesAugust 3, 2024 | insidertrades.comRalf Kuriyel Sells 4,465 Shares of Repligen Co. (NASDAQ:RGEN) StockAugust 20 at 12:56 PM | markets.businessinsider.comBuy Rating Affirmed: Overlooked Long-Term Benefits of Repligen’s Potential Maravai AcquisitionAugust 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 20 at 2:54 AM | markets.businessinsider.comJefferies Remains a Hold on Repligen (RGEN)August 18, 2024 | americanbankingnews.comRepligen (NASDAQ:RGEN) Sees Strong Trading VolumeAugust 17, 2024 | msn.comDo You Believe in the Growth Prospects of Repligen Corp. (RGEN)?August 16, 2024 | reuters.comExclusive: Repligen in bid for reagent vendor Maravai, sources sayAugust 15, 2024 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 2, 2024 | fool.comHere's Why Shares in This Hot Healthcare Stock Surged This WeekAugust 1, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Repligen Amid Strong Growth Prospects and Market ResilienceAugust 1, 2024 | markets.businessinsider.comRepligen’s Buy Rating Affirmed Amid Strong Growth and Strategic InitiativesAugust 1, 2024 | msn.comThese Analysts Revise Their Forecasts On Repligen Following Q2 ResultsJuly 31, 2024 | seekingalpha.comRepligen Corporation (RGEN) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Repligen (RGEN)July 31, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Repligen (RGEN)July 31, 2024 | msn.comRepligen Corporation (NASDAQ:RGEN) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | marketwatch.comRepligen Shares Rise 11% After 2Q Financial ResultsSee More Headlines Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2024Today8/22/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees1,783Year Founded1981Price Target and Rating Average Stock Price Target$189.57 High Stock Price Target$220.00 Low Stock Price Target$155.00 Potential Upside/Downside+23.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.25 Trailing P/E Ratio611.82 Forward P/E Ratio105.48 P/E Growth5.27Net Income$41.58 million Net Margins-0.32% Pretax Margin1.69% Return on Equity3.36% Return on Assets2.41% Debt Debt-to-Equity Ratio0.26 Current Ratio6.65 Quick Ratio5.56 Sales & Book Value Annual Sales$638.76 million Price / Sales13.41 Cash Flow$3.14 per share Price / Cash Flow48.76 Book Value$35.31 per share Price / Book4.33Miscellaneous Outstanding Shares56,010,000Free Float55,205,000Market Cap$8.57 billion OptionableOptionable Beta0.95 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Anthony J. Hunt (Age 60)CEO & Director Comp: $885kMr. Olivier Loeillot (Age 54)President & Chief Commercial Officer Comp: $1.49MMr. Jason K. Garland (Age 50)CFO & Chief Compliance Officer Comp: $282.99kMr. James R. Bylund (Age 60)Chief Operating Officer Comp: $472.18kMs. Christine Gebski (Age 56)Senior Vice President of Filtration & Chromatography Comp: $396.09kMr. Ralf Kuriyel (Age 66)Senior Vice President of Research & Development Comp: $401.74kMr. Keith Lee RobinsonChief Information OfficerMs. Sondra S. NewmanGlobal Head of Investor RelationsMs. Kimberly A. CornwellGeneral Counsel & Global Head of LegalDr. Jaime M. Humara Ph.D.Senior Vice President of Global MarketingMore ExecutivesKey CompetitorsQiagenNYSE:QGENAcceleron PharmaNASDAQ:XLRNBio-TechneNASDAQ:TECHCRISPR TherapeuticsNASDAQ:CRSPDenali TherapeuticsNASDAQ:DNLIView All CompetitorsInsiders & InstitutionsTruist Financial CorpSold 680 shares on 8/21/2024Ownership: 0.005%Susquehanna International Group LLPBought 6,800 shares on 8/16/2024Ownership: 0.000%NBW Capital LLCBought 2,451 shares on 8/15/2024Ownership: 0.064%APG Asset Management US Inc.Bought 359 shares on 8/15/2024Ownership: 0.027%Toronto Dominion BankBought 75 shares on 8/15/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions RGEN Stock Analysis - Frequently Asked Questions How have RGEN shares performed this year? Repligen's stock was trading at $179.80 at the beginning of 2024. Since then, RGEN stock has decreased by 17.0% and is now trading at $149.30. View the best growth stocks for 2024 here. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday, July, 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts' consensus estimates of $0.33. Repligen's revenue for the quarter was down 3.2% compared to the same quarter last year. What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Does Repligen have any subsidiaries? The following companies are subsidiaries of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and more. Who are Repligen's major shareholders? Top institutional shareholders of Repligen include Bank of New York Mellon Corp (2.45%), Conestoga Capital Advisors LLC (1.69%), Thrivent Financial for Lutherans (1.08%) and Dimensional Fund Advisors LP (0.77%). Insiders that own company stock include Anthony Hunt, Karen A Dawes, Jon Snodgres, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus, Manner Carrie Eglinton, Nicolas Barthelemy and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU) and Walt Disney (DIS). This page (NASDAQ:RGEN) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGEN Stock Alerts